Novel Chewable Pleuran-Based Supplement Decreases Respiratory Tract Infections in Children: A Randomised Controlled Trial.

Adv Ther · 2025 · PMC12618377 · PMID 41085920

Europe PMC DOI

hedged sentences

0.2250

closest p · 4.5× alpha

0.3430

boldest claim

The sentences

showed a trendP = 0.225not close (p > 0.1)

Analysis of individual RTI subtypes showed a trend toward shorter duration of common cold (8.88 ± 8.79 vs. 10.32 ± 8.57; P = 0.225) and tonsillopharyngitis (1.88 ± 4.12 vs. 2.67 ± 4.74; P = 0.186) in the active group (Table 2 ).

also in 53,322 other papers

did not reach statistical significanceP = 0.343not close (p > 0.1)

Although the mean duration of total RTIs was shorter in children given the pleuran-based supplement compared to those receiving the active placebo, the difference did not reach statistical significance (15.17 ± 10.13 vs. 16.60 ± 11.88; P = 0.343).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.